Michael Barbella, Managing Editor04.29.24
Heart Test Laboratories Inc. d/b/a HeartSciences has been granted a Canadian patent for its MyoVista Energy Waveform technology, which is used to assess heart disease risk.
“Millions of conventional ECG’s are performed worldwide every week and AI-ECG technology is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, while reducing treatment costs," HeartSciences CEO Andrew Simpson said. "We are pleased to receive this latest patent grant in Canada. Over recent years we have built an international intellectual property portfolio across major markets which we expect will provide competitive advantage and intrinsic corporate value as AI is set to drive significant growth in the ECG market to $25 billion per year by 2032.”1
The company's MyoVista Wavelet ECG (wavECG) Cardiac Testing Device has been developed to address the fact that most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and left ventricular diastolic dysfunction (LVDD). The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired ECG signal, which is then analyzed using artificial intelligence. This innovation uses proprietary technology designed to be used by physicians as part of an overall heart disease risk assessment to help determine whether a patient should receive further testing, evaluation, and/or treatment.
The MyoVista wavECG Device is a 12-lead resting electrocardiograph (ECG) device that features wavECG Technology plus the capabilities of a full-featured conventional 12-lead resting ECG including analysis using the University of Glasgow Algorithm. The conventional ECG and MyoVista wavECG test results are displayed independently.
The U.S. Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences that are scheduled to last through March 2031 and August 2040. In addition, HeartSciences has 14 international design registrations and 19 international utility patents granted in various jurisdictions: China, Japan, South Korea, the United Kingdom, France, Germany, Mexico, the United Arab Emirates, Brazil, and Australia, with expiration dates ranging from September 2036 through March 2037.
Heart Test Laboratories Inc. applies artificial intelligenceI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility in order to make it a more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences claims to have one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform.
Reference
1 Precedence Research 2023
“Millions of conventional ECG’s are performed worldwide every week and AI-ECG technology is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, while reducing treatment costs," HeartSciences CEO Andrew Simpson said. "We are pleased to receive this latest patent grant in Canada. Over recent years we have built an international intellectual property portfolio across major markets which we expect will provide competitive advantage and intrinsic corporate value as AI is set to drive significant growth in the ECG market to $25 billion per year by 2032.”1
The company's MyoVista Wavelet ECG (wavECG) Cardiac Testing Device has been developed to address the fact that most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and left ventricular diastolic dysfunction (LVDD). The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired ECG signal, which is then analyzed using artificial intelligence. This innovation uses proprietary technology designed to be used by physicians as part of an overall heart disease risk assessment to help determine whether a patient should receive further testing, evaluation, and/or treatment.
The MyoVista wavECG Device is a 12-lead resting electrocardiograph (ECG) device that features wavECG Technology plus the capabilities of a full-featured conventional 12-lead resting ECG including analysis using the University of Glasgow Algorithm. The conventional ECG and MyoVista wavECG test results are displayed independently.
The U.S. Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences that are scheduled to last through March 2031 and August 2040. In addition, HeartSciences has 14 international design registrations and 19 international utility patents granted in various jurisdictions: China, Japan, South Korea, the United Kingdom, France, Germany, Mexico, the United Arab Emirates, Brazil, and Australia, with expiration dates ranging from September 2036 through March 2037.
Heart Test Laboratories Inc. applies artificial intelligenceI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility in order to make it a more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences claims to have one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform.
Reference
1 Precedence Research 2023